Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
276.33 (USD) • At close September 19, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Alnylam Pharmaceuticals, Inc. |
Symbool | ALNY |
Munteenheid | USD |
Prijs | 276.33 |
Beurswaarde | 35,475,521,730 |
Dividendpercentage | 0% |
52-weken bereik | 141.98 - 287.55 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB |
Website | https://www.alnylam.com |
An error occurred while fetching data.
Over Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)